Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Risankizumab IV vs SC in Healthy Volunteers
NCT06487572Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at 140 days, Maximum Observed Serum Concentration (Cmax) of Risankizumab at 140 days and 2 more. Started Jul 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06487572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487572.